Similar Papers

Paper Title
Journal
Date
Author
Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials
Maria-Victoria Mateos ... Xavier Leleu
Blood | VOL. 130
Maria-Victoria Mateos, et. al.Maria-Victoria Mateos ... Xavier Leleu
25 Jun 2021
Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials
Maria-Victoria Mateos ... Xavier Leleu
Blood | VOL. 132
Maria-Victoria Mateos, et. al.Maria-Victoria Mateos ... Xavier Leleu
29 Nov 2018
Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial
Robert J Pelham ... Meletios A Dimopoulos
Blood | VOL. 130
Robert J Pelham, et. al.Robert J Pelham ... Meletios A Dimopoulos
07 Dec 2017
Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study
Meletios A Dimopoulos ... Ruben Niesvizky
Blood | VOL. 130
Meletios A Dimopoulos, et. al.Meletios A Dimopoulos ... Ruben Niesvizky
25 Jun 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.